Callan JMB Inc. (NASDAQ: CJMB) announced that it will serve as an independent infrastructure and oversight partner in a U.S. collaboration led by DifGen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp (Attune Biotech), and SGP Holdings. The partnership focuses on U.S. technology transfer, formulation development, and manufacturing scale‑up for the JKB‑122 (Lodonal ™) immune‑restoration platform, a multi‑indication program targeting post‑infectious immune dysfunction.
The collaboration will give Callan JMB responsibility for independent validation of manufacturing, quality systems, and supply‑chain operations, as well as packaging, serialization, and product traceability coordination to meet federal standards for agencies such as BARDA, the Department of Defense, and the Veterans Affairs. The goal is to prepare the platform for Phase 2b/3 clinical development and potential large‑scale manufacturing and deployment.
This partnership represents a significant expansion of Callan JMB’s service portfolio beyond its traditional cold‑chain logistics and emergency‑preparedness services, creating a new revenue stream tied to a high‑profile therapeutic program and positioning the company to capture a share of the growing immune‑restoration market.
While the collaboration is strategically important, Callan JMB remains unprofitable. In Q3 2025 the company reported a net loss of $2.7 million, a decline from the prior year, and revenue fell 50.3% from $13.2 million to $6.6 million, with an operating margin of –34.7% versus 16.7% the year before. These figures underscore the financial headwinds the company faces as it expands into regulated manufacturing oversight.
CEO Wayne Williams said, “Callan JMB has deep experience supporting complex, regulated programs where execution, compliance, and visibility are critical.” He added, “This program is unique in that it is built around a platform formulation and manufacturing strategy across multiple dose strengths and multiple indications. As the platform expands into additional indications, we look forward to supporting not only manufacturing and formulation development, but also a broader role in supporting future clinical development programs built on this platform.”
The new collaboration could provide a much‑needed revenue stream for Callan JMB, but the company’s financial trajectory suggests that the partnership will need to generate significant incremental revenue to offset ongoing losses. Investors will likely view the deal as a strategic bet on the company’s ability to leverage its regulatory expertise while still monitoring its profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.